Saturday 17 October 2026
Export KPRX’s income statement to Excel — free account
Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.
2.40
0.01
−0.41%
Follow KPRX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 1.51 | — |
Piotroski F-Score |
— | — | 4 | 4 | 1 | — | — | — | — | — |
P/S ratio |
0.00 | 27.69 | 9.60 | 7.32 | 6.98 | — | — | — | 0.68 | — |
Altman Z-Score |
(15.32) | (12.30) | (9.27) | (10.13) | (8.85) | — | — | — | (3.16) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 1.49 | — |
Altman Z″-Score (non-manufacturers) |
(37.71) | (30.81) | (22.49) | (33.16) | (24.11) | — | — | — | (5.20) | — |
P/Operating CF |
(7.07) | (10.82) | (8.27) | (12.27) | (13.29) | — | — | — | (5.67) | — |
Beneish M-Score |
— | (5.65) | (0.17) | (1.85) | 3,748.65 | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 1.85 | 4.79 | 2.33 | — | — | — | 0.50 | — |
Price to Tangible BV |
0.00 | 0.00 | 5.09 | 32.88 | 0.00 | — | — | — | 0.67 | — |
EV/Sales |
0.00 | 13.95 | 4.96 | 6.45 | 6.70 | — | — | — | (0.74) | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | — |
EV/Operating CF |
(1.30) | (1.22) | (0.79) | (3.43) | (2.98) | — | — | — | (1.62) | — |
EV/FCF |
(1.29) | (1.22) | (0.79) | (3.41) | (2.95) | — | — | — | (1.62) | — |
Quick Ratio |
0.50 | 0.53 | 2.08 | 2.67 | 0.64 | 5.21 | 2.24 | 2.76 | 4.60 | 5.62 |
Current Ratio |
0.57 | 0.57 | 2.19 | 3.06 | 0.87 | 5.59 | 2.35 | 2.90 | 4.94 | 5.99 |
Net Debt/EBITDA |
0.27 | 0.54 | 0.74 | 0.54 | 0.13 | 0.77 | 0.49 | 0.20 | (5.78) | 1.33 |
Debt/Assets |
0.17% | 0.03% | 0.00% | 0.00% | 1.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.05) | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.07 | 0.03 | 0.12 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.64 | 0.00 |
Operating CF/Net income |
0.63 | 0.49 | 1.00 | 1.15 | 1.07 | 0.78 | 0.77 | 0.73 | 2.38 | 0.92 |
Capex/Depreciation |
(2.12) | (1.92) | (0.52) | 0.00 | (0.60) | (0.02) | 0.15 | 0.00 | (0.05) | (4.47) |
Interest Coverage |
(44,489.67) | (12,132.67) | (10,844.70) | (23,696.67) | (1,635.45) | (2,063.16) | (1,431.34) | (1,133.95) | 210.76 | (641.55) |
| (463.52%) | 1,171.64% | (308.49%) | (91.23%) | (83.93%) | (113.30%) | (104.54%) | (148.94%) | 22.56% | (51.74%) | |
| (138.72%) | (109.98%) | (75.64%) | (58.19%) | (53.99%) | (77.72%) | (70.00%) | (80.55%) | 14.32% | (35.68%) | |
ROIC |
0.00% | 0.00% | (727.17%) | (156.13%) | (48.66%) | (132.31%) | (141.35%) | (215.23%) | 0.00% | 0.00% |
Return on Tangible Assets |
428.21% | 209.20% | (232.13%) | (242.51%) | 3,012.20% | (184.71%) | (304.33%) | (419.17%) | 15.17% | (59.51%) |
Average Days of Receivables |
29.34 | 21.23 | 4.06 | 0.67 | 2,745.04 | 0.00 | 0.00 | 0.00 | 19.85 | 0.00 |
Research and Development Expense of Revenue |
1,258.40% | 2,535.07% | 487.49% | 200.65% | 29,471.07% | 0.00% | 0.00% | 0.00% | 48.95% | 0.00% |
Selling, General and Administrative Expense of Revenue |
835.74% | 1,137.77% | 268.77% | 164.02% | 38,502.48% | 0.00% | 0.00% | 0.00% | 34.60% | 0.00% |
Intangible Assets out of Total Assets |
0.56 | 0.38 | 0.40 | 0.56 | 0.87 | 0.53 | 0.58 | 0.64 | 0.18 | 0.09 |
Share Based Compensation of Revenue |
76.35% | 213.57% | 52.97% | 31.73% | 5,982.64% | 0.00% | 0.00% | 0.00% | 4.10% | 0.00% |
Graham Net Nets |
(0.41) | (0.49) | 0.19 | 0.03 | (0.17) | — | — | — | 1.49 | — |
Graham Number |
6,144.57 | 9,198.31 | 0.00 | 0.00 | 0.00 | — | — | — | 18.11 | — |
Earnings Yield |
(89.85%) | (83.90%) | (70.94%) | (22.06%) | (30.30%) | — | — | — | 66.38% | — |
Free Cash Flow Yield |
(58.04%) | (41.44%) | (65.78%) | (25.87%) | (32.55%) | — | — | — | 66.92% | — |
Revenue per Share |
418.31 | 156.73 | 250.38 | 305.23 | 0.95 | 0.00 | 0.00 | 0.00 | 4.14 | 0.00 |
Operating CF per Share |
(5,258.25) | (2,487.88) | (1,643.11) | (926.57) | (571.66) | (398.34) | (128.27) | (17.76) | 2.21 | (2.39) |
Capex per Share |
(6.87) | (14.23) | (3.03) | 0.00 | (1.57) | (2.38) | 0.08 | 0.00 | 0.00 | (0.03) |
Free Cash Flow per Share |
(5,265.12) | (2,502.12) | (1,646.14) | (926.57) | (573.23) | (400.72) | (128.19) | (17.76) | 2.21 | (2.42) |
Cash per Share |
2,272.00 | 3,002.31 | 1,212.76 | 429.17 | 92.63 | 293.09 | 73.37 | 4.56 | 6.92 | 4.10 |
Shareholders Equity per Share |
(205.87) | (741.12) | 1,353.98 | 752.56 | 760.13 | 544.00 | 140.31 | 11.36 | 6.65 | 3.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(205.87) | (741.12) | 1,353.98 | 752.56 | 760.13 | 544.00 | 140.31 | 11.36 | 6.65 | 3.87 |
Free Cash Flow |
(8.42) | (6.51) | (10.86) | (8.15) | (7.34) | (10.74) | (10.42) | (9.56) | 8.55 | (10.07) |
Working Capital |
(3.15) | (6.37) | 4.61 | 2.91 | (0.26) | 7.38 | 4.41 | 3.10 | 23.70 | 18.12 |
Capital Expenditures |
(0.01) | (0.04) | (0.02) | — | (0.02) | (0.06) | 0.01 | — | (0.01) | (0.11) |
Net Current Asset Value |
(5.91) | (7.77) | 3.13 | 0.83 | (3.85) | 3.44 | 0.41 | (2.86) | 18.98 | 13.62 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | — |
Capex to Sales |
0.02 | 0.09 | 0.01 | 0.00 | 1.66 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 2.83 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.35 | 0.89 | 3.08 | 1.09 | 55.18 | 0.75 | 6.40 | 23.73 | 0.27 |
Cash ROIC |
(253.60%) | (110.56%) | (64.13%) | (78.41%) | (65.55%) | (47.87%) | (59.99%) | (111.59%) | 16.27% | (30.32%) |
Accounts Receivable Turnover |
1.36 | 10.52 | 78.50 | 230.56 | 0.25 | 0.00 | 0.00 | 0.00 | 10.97 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.49 | 0.04 | 0.02 | 0.01 | 0.05 | 0.31 | 0.95 | 1.71 | 1.46 | 2.09 |
Average Payables |
0.91 | 1.06 | 0.38 | 0.14 | 0.32 | 0.30 | 0.58 | 0.61 | 0.31 | 0.74 |
Average Assets |
9.62 | 12.02 | 14.29 | 12.20 | 12.71 | 17.72 | 19.40 | 16.20 | 25.10 | 30.37 |
Average Common Equity |
2.88 | (1.13) | 3.50 | 7.78 | 8.18 | 12.15 | 12.99 | 8.76 | 15.93 | 20.94 |
Columns are period end dates